Showing 361-370 of 370 results for "".
- New Data Show Stelara Effective for Psoriatic Arthritishttps://practicaldermatology.com/news/20121203-new_data_finds_stelara_effective_for_psoriatic_arthritis/2459669/Findings from the PSUMMIT II Phase 3 investigational study showed patients with active psoriatic arthritis receiving Stelara (ustekinumab, Jannsen) demonstrated significant improvements in signs and symptoms of the disease. Significantly more patients receiving either Stelara 45 mg or 90 mg achieve…
- Provectus Pharmaceuticals Publishes Patent Application, PV-10 Resultshttps://practicaldermatology.com/news/20121002-provectus_pharmaceuticals_publishes_patent_application/2459722/Provectus Pharmaceuticals, Inc. announced that a patent application has been published for US and international patents covering the combination of local and systemic immunomodulative therapies for cancer treatment. The patent, entitled "Combination of Local and Systemic Immunomodulative Therapies …
- Provectus Pharmaceuticals to Present Data on PV-10https://practicaldermatology.com/news/20120918-provectus_pharmaceuticals_to_present_data_on_pv-10/2459733/Provectus Pharmaceuticals, Inc. announced that final efficacy data from its Phase II trial of PV-10 in patients with Stage III-IV melanoma will be presented, including response rate and time-to-event (progression free survival and overall survival), at the ESMO 2012 (European Society for Medical On…
- OPTiM Trial for T-VEC in Unresectable Melanomahttps://practicaldermatology.com/news/20120604-optim_trial_for_t-vec_in_unresectable_melanoma/2459791/The OPTiM trial for T-VEC (formerly OncoVEXGM-CSF), an oncolytic HSV1 that selectively replicates in tumors, is now underway, according to a presentation by Kaufman, et al. at ASCO 2012. The randomized phase 3 trial will evaluate the efficacy and safety of talimogene laherparepvec (T-VEC) compared …
- GlaxoSmithKline Launches Combination Trials for Metastatic Melanomahttps://practicaldermatology.com/news/20120604-glaxosmithkline_launches_combinations_trial_for_metastatic_melanoma/2459792/GlaxoSmithKline has begun a Phase III program evaluating the combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib in patients with BRAF mutation-positive metastatic cutaneous melanoma. The COMBI-d (Combination of MEK and BRAF Inhibitors versus dabrafenib) trial is a Phas…
- Efficacy Data for LaViv Now Publishedhttps://practicaldermatology.com/news/20120418-efficacy_data_for_laviv_now_published/2459822/Data demonstrating that LaViv (azficel-T, Fibrocell Science, Inc.) is effective for the aesthetic improvement of moderate to severe smile lines are now published online in Dermatologic Surgery. The combined results of two identically-designed, Phase III, multi-center, randomized, double-blind, plac…
Using the REVIAN Red System for Your Hair Loss Patients
https://practicaldermatology.com/topics/hair-nails/using-the-revian-red-system-for-your-hair-loss-patients/19754/Hear a few practical insights from hair loss experts Suneel Chilukuri, MD, Joel Cohen, MD and Michael Gold, MD about how they incorporate the new REVIAN Red dual-band LED wireless cap and smart app in their practices! REVIAN Red is indicated to treat androgenetic alopecia and to promote hair growthDermWireTV: AbbVie's Science of Skin Panel, Monkeypox Warning, Recommendations on Skin Cancer Detection Devices, UV Filters and Aquatic Life
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-abbvies-science-of-skin-panel-monkeypox-warning-recommendations-on-skin-cancer-detection-devices-uv-filters-and-aquatic-life/20131/“The Science of Skin: United Beyond the Surface” program sponsored by AbbVie brings together leading dermatologists and patients or caregivers of patients with dermatologic disease to explore the burden of skin diseases on diverse populations and the need for optimized treatment approaches. Seemal DLearn More About REVIAN® Red Hair Growth System
https://practicaldermatology.com/topics/hair-nails/learn-more-about-revian-red-hair-growth-system/19750/Discover a new option for hair loss patients! REVIAN Red is a patented dual-band LED wireless cap for at-home use ten minutes daily. Click Here to Become a REVIAN Red Professional. REVIAN Red is indicated to treat androgenetic alopecia and to promote hair growth in males who have Norwood-Hamilton clTo Be Shorr: Importance of Using Technology to Its Fullest Extent
https://practicaldermatology.com/topics/practice-management/to-be-shorr-importance-of-using-technology-to-its-fullest-extent/18605/Some of the administrative tasks that bog down a practice can be automated—and your existing vendors may have the applications and technology you need to make it happen. Be sure to investigate the services your vendors provide, many of which you already pay for, to make the most of your practice tec
- Previous
- Next